
VERU
USDVeru Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$2.580
Kõrge
$2.650
Madal
$2.580
Maht
0.18M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
42.5M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
0.18M
Börs
NCM
Valuuta
USD
52 nädala vahemik
Tehisintellekti analüüsiaruanne
Viimati uuendatud: 10. nov 2025VERU Stock Analysis: Veru Inc. Navigates Volatility Amid Fundamental Challenges
Market Snapshot
Current Price: $2.61 (as of 2025-11-10) 52-Week Range: $2.42 - $14.20 Market Cap: $41.89M | P/E Ratio: -9.00 Recent Volatility: Sharp decline from $4.43 (Oct 20) to $2.61, with erratic volume patterns
Recent Performance: Turbulent Descent
Veru’s stock has been in a clear downtrend since mid-October, shedding 41% from its October peak. Key observations:
- Public Offering Impact: The $25M offering on Oct 30 likely triggered selling pressure, with shares dropping 12% the following day.
- Volume Anomalies: Unusually high trading volume on Oct 30 ($765,700) and Nov 3 ($489,500) suggests panic selling or institutional exits.
- Support Zone: Recent closes near $2.52-$2.58 align with its 52-week low, indicating this range may act as temporary support.
Technical Signals: Mixed Messages
- Bullish DMI: +DI (15.4) > -DI (14.1) with ADX at 19.0 implies a weak uptrend could form if buyers step in.
- Volume Surge: 1.9x average volume on Nov 10 hints at renewed interest, but this could reflect short-term positioning rather than sustainable demand.
- MACD Death Cross: Bearish momentum confirmed as MACD (0.0119) fell below signal line (0.0162) despite AI’s upward projections.
Fundamentals: Value Trap or Hidden Potential?
- Contradictory Valuation: While the P/E (-9.00) appears broken due to negative earnings, the recommendation claims it’s “0.4x industry average” (likely referencing EBITDA multiples or forward estimates). Proceed with skepticism.
- **High-Risk
Seotud uudised
Veru to Present Two Abstracts at ObesityWeek 2025
MIAMI, FL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
Veru Announces Pricing of $25 Million Public Offering
MIAMI, FL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
Tehisintellekti ennustusBeta
Tehisintellekti soovitus
Uuendatud kell: 10. nov 2025, 14:42
58.4% Kindlus
Risk ja kauplemine
Sisenemispunkt
$2.52
Võta kasum
$2.61
Peata kahjum
$2.30
Põhitegurid
Seotud aktsiad
FIAC
Focus Impact Acquisition Corp.
GPAT
GP-Act III Acquisition Corp. Ordinary Share
LPRO
Open Lending Corporation
CMMB
Chemomab Therapeutics Ltd. American Depositary Share
NMTC
NeuroOne Medical Technologies Corporation
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.